Tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks and has stronger body-composition results. Semaglutide has the longer safety history, cardiovascular outcomes data, kidney outcomes data, and an oral formulation. Oral semaglutide What about oral semaglutide (Rybelsus)
CMS Issues Proposed IPPS Rule The Centers for Medicare & Medicaid Services (CMS) has released its proposed inpatient prospective payment system (IPPS) rule for fiscal year 2023, with changes that would impact reporting used
The solution is no longer protected against microbial growth
Discussion of costs and insurance coverage is important given that BPC-157, as an unapproved drug, typically is not covered by health insurance
Mechanism, dosing, evidence, and what the research does not yet support